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Abstract
Background: To report the prevalence of pleural plaques in a lung cancer screening trial by low-dose computed
tomography (LDCT) and to test the association with incidence of lung cancer and mortality.
Methods: The LDCT of 2303 screenees were retrospectively reviewed with the specific aim of describing the
prevalence and features of pleural plaques. Self-administered questionnaire was used to assess asbestos exposure.
Frequency of lung cancer, lung cancer mortality, and overall mortality were detailed according to presence of
pleural findings. Statistical analyses included comparison of mean or median, contingency tables, and Cox model
for calculation of hazard ratio (HR) and its 95% confidence interval (CI).
Results: Among male screenees, 31/1570 (2%) showed pleural abnormalities, 128/1570 (8.2%) disclosed asbestos
exposure, 23/31 (74.2%) subjects with pleural plaques consistently denied exposure to asbestos. There was a trend
for higher frequency of lung cancer among subjects with pleural plaques (9.7% vs 4.2%). Lung cancer in subjects
with pleural plaques was always diagnosed in advanced stage. Subjects with pleural plaques showed HR 5.48
(95% CI 1.61–18.70) for mortality from lung cancer.
Conclusions: Pleural plaques are a risk factor for lung cancer mortality that can be detected in lung cancer
screening by LDCT, also in subjects that are not aware of asbestos exposure.
Trial registration: NCT02837809 - Retrospectively registered July 1, 2016 - Enrolment of first participant
September 2005.
Keywords: Lung cancer screening, Pleural abnormalities, Asbestos exposure, Pleural plaques, Self-disclosure of
asbestos exposure, Post-test refinement of individual risk
* Correspondence: mario.silva@unipr.it
1Department of Medicine and Surgery (DiMeC), Section of Radiology, Unit of
Surgical Sciences, University of Parma, Padiglione Barbieri, Via Gramsci 14,
43126 Parma, Italy
2Department of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Silva et al. BMC Pulmonary Medicine  (2017) 17:155 
DOI 10.1186/s12890-017-0506-3
Background
Lung cancer screening by low-dose computed tomography
(LDCT) has the main purpose of reducing lung cancer
mortality in subjects that have several risk factors contrib-
uting to increased risk of lung cancer [1]. Asbestos expos-
ure is a well-known risk factor for thoracic malignancies
and non-malignant respiratory diseases [2–5], hence, the
majority of lung cancer risk models include exposure to as-
bestos for pre-test calculation of lung cancer risk [3, 6, 7].
However, there is limited reliability on reference methods
for the assessment of life-time exposure from occupational
and, notably, non-occupational inhalation.
Signs of asbestos exposure can be detected by LDCT,
with variable degrees of accuracy. Pleural plaques are
among the chest abnormalities significantly related with
exposure to asbestos [8, 9]. In the setting of professional
exposure to asbestos, several studies reported the associ-
ation between reduced survival and asbestos-related
LDCT signs, including pleural plaques [4, 10]. The de-
tection of pleural plaques and their prognostic value in
non-occupational setting has not been investigated, yet.
Lung cancer screening trials by LDCT provide the
unique opportunity of investigating pleural plaques out
of the specific setting of professional surveillance.
The aim of this study was to describe the prevalence
of pleural plaques in a population of lung cancer screen-
ing participants, and to test their relation with incidence
of lung cancer and mortality.
Methods
The Institutional Review Board approved the Multicen-
ter Italian Lung Detection (MILD) protocol, and written
informed consent was obtained from all participants.
Informed consent included retrospective evaluation of
MILD data, as performed in this study. Therefore, spe-
cific consent was waived for this study. Eligibility criteria
were as follows: age 50–75 years, current or former
(having quit <10 years before enrollment) smokers with
a tobacco burden ≥20 pack-years, and no history of can-
cer in the 5 years before enrollment. Details on screen-
ing strategy and lung cancer specific mortality rates of
the MILD trial are published elsewhere [11]. In brief, the
MILD trial enrolled a total of 4099 participants from
September 2005 to January 2011. These subjects were
randomly assigned to two groups: the early detection
group (2376 participants) received a LDCT either every
12 months (1190 participants) or every 24 months (1186
participants), and the control group (1723 participants)
received only primary prevention program with pulmon-
ary function test and blood sample collection.
This investigation aimed to evaluate pleural abnormal-
ities on baseline LDCT, and was thus based on the early
detection group only. Baseline LDCT was available for
2303 out of 2376 participants (1570 men and 733
women; median age 60 years, interquartile range - IQR -
55 to 65 years). These subjects were evaluated for
pleural abnormalities. The MILD protocol included self-
administered questionnaire about medical history (i.e.
oncologic history, cardio-vascular and respiratory anam-
nesis, metabolic diseases, and family history of lung
cancer), smoking history (i.e. cigarette smokers were dif-
ferentiated from other smokers, duration of smoking,
amount of daily cigarette, pack-years, and Fagerstrom
test) [12], exposure to asbestos, respiratory symptoms,
subjective awareness of lung cancer risk related to smok-
ing, and willing to quitting smoking [13]. Also, height
and weight were recorded and body mass index (BMI)
was calculated.
Visual assessment of pleural plaques on LDCT
LDCT technique
LDCT was performed with a 16-detector CT scanner
(Somatom Sensation; Siemens Healthcare, Forchheim,
Germany) without contrast agent, and with standardized
low dose acquisition protocol: potential 120 kVp, current
30 effective mAs, collimation 0.75 mm, rotation time
0.5 s, and pitch 1.5. For each LDCT examination, the re-
construction protocol was as follows: slice thickness
1 mm, slice increment 1 mm, and kernel b50. For this
study, the reconstructed images were stored to a
dedicated workstation for diagnostic work-up (Osirix,
Pixmeo SARL, Bernex, Switzerland); window width
(WW) and window level (WL) were optimized for
assessment of pleura (soft tissue setting: WW 350 HU
and WL 50 HU) and lung parenchyma (lung setting:
WW 1600 and WL -600 HU).
Pleural findings
LDCTs were reviewed by two radiologists for the detec-
tion of pleural abnormalities (both radiologists had three-
year experience in lung cancer screening LDCT: 1201
LDCTs read by MS and 1102 LDCTs read by DC). A se-
nior radiologist (NS, with 10-year experience in lung can-
cer screening LDCT) reviewed LDCT of all subjects with
pleural abnormalities and selected those evocative of as-
bestos exposure, as described thereafter. Pleural plaques
and diffuse pleural thickening were deemed findings
evocative of asbestos exposure [8, 9]. In particular, pleural
plaques were described as solid thickening of pleural
surface with clear-cut edges, with or without calcification
[14, 15] (Fig. 1). Diffuse pleural thickening was described
as single continuous pleural thickening thicker than
3 mm, larger than 5 cm on axial plane, and longer than
8 cm in z-axis [8, 14]. From now on, all pleural abnormal-
ities evocative of asbestos exposure will be referred as
pleural plaques. All pleural plaques were visually scored
according to a pre-formatted score sheet, adapted from
the literature [14–17], namely: a) distribution according to
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side (unilateral or bilateral) and pleural anatomical com-
partment (subcostal, para-mediastinal, diaphragmatic,
and fissural); b) presence of calcifications; c) aspect was
described as smooth or nodular; d) cumulative extent
was classified into 4 groups: smaller than 1 cm, be-
tween 1 cm and 25% of pleural surface, 25%–50% of
pleural surface, and > 50% of pleural surface; e) thick-
ness was classified into 4 groups: < 2 mm, 2–5 mm, 5–
10 mm, and > 10 mm.
Self-reported asbestos exposure
The self-administered questionnaire included disclosure of
asbestos exposure. It was administered at the recruitment
appointment and at any following LDCT appointment.
Subjects with consistent positive disclosure about asbestos
exposure over the consecutive questionnaires were
deemed exposed. Conversely, non-exposed subjects were
those with consistent negative disclosure or inconsistent
disclosures along the consecutive questionnaires (e.g. posi-
tive disclosure at baseline questionnaire and negative dis-
closure at follow-up, or vice versa). The self-reported
asbestos exposure was compared with the presence of
pleural plaques to investigate awareness of exposure.
Frequency of lung cancer and assessment of cause of
mortality
Lung cancers were recorded from the surgical registry,
in particular, histology and stage were reported [18].
Mortality from lung cancer and mortality from any
cause were retrieved from the National Registry Office
database. Data were updated to April 2016.
Statistical analysis
Statistical analysis was selectively performed on male
population to avoid multivariate model bias from gender-
related variables (e.g. height, weight, and BMI) related to
the odd distribution of pleural plaques between genders.
The continuous variables were given as median with their
interquartile range (IQR) and were analyzed using a two-
sided Student’s t-test, if data were normally distributed
(based on the Shapiro-Wilk statistic), or a two-sided
Wilcoxon rank-sum test, if otherwise. The categorical
variables were given as numbers and percentages and
were analyzed using the contingency table analysis with
the Chi-square or Fisher’s test, as appropriate.
The Cox model adjusted for age, BMI, pack-years, and
self-disclosure of asbestos exposure was used to calcu-
late the hazard ratio (HR) and the corresponding 95%
confidence intervals (CI) for lung cancer incidence, lung
cancer mortality, mortality from causes different from
lung cancer, and overall mortality. All tests were two-
sided and a p-value < 0.05 was considered as statistically
significant. All statistical analyses were performed with
MedCalc 12 (MedCalc Software, Belgium).
Results
Visual assessment of pleural plaques on LDCT
Pleural plaques were reported in 33/2303 subjects
(1.4%), in particular 31/1570 men (2.0%) and 2/733
women (0.3%) (p < 0.001). Demographics, biometrics,
smoking history, and self-disclosure of asbestos exposure
of male screenees were reported in Table 1, according to
presence of pleural plaques. Men with pleural plaques
were older (p = 0.005), with similar biometrics and
smoking history compared to men without pleural pla-
ques. The geographic area of screenee provenance was
summarized in Fig. 2 and the distribution of pleural pla-
ques was detailed as the ratio of screenees from each
area of provenance. LDCT features of pleural plaques
were summarized in Table 2, notably pleural effusion
was reported in 1/31 men (3.2%) and it was not associ-
ated with lung cancer or mesothelioma.
Self-reported asbestos exposure
Asbestos exposure was consistently self-reported by 128/
1570 men (8.2%), whereas 68/1570 (4.3%) provided in-
consistent disclosure, and 1374/1570 (87.5%) consist-
ently denied asbestos exposure. The consistent self-
reported exposure to asbestos was significantly related
to presence of pleural plaques (p = 0.003; Table 1), how-
ever the majority of men with pleural plaques consist-
ently denied exposure to asbestos (23/31, 74.2%).
Frequency of lung cancer and cause of mortality
Sixty-eight lung cancers were diagnosed in 1570 men
over 14,533.3 person-years (467/100,000 person-years),
Fig. 1 a-c Pleural plaques. a-b - Transverse CT image of the chest
shows smooth solid thickening of pleural surface with clear-cut edge.
c – Coronal reconstruction of the chest shows smooth solid thickening
of pleural surface above the diaphragm, with scant calcification
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Fig. 2 Geographic area of provenance of screenees are summarized according to numeric categories: 1–10 screenees, 11–100 screenees, 101–500
screenees, and > 500 screenees. The geographic distribution of pleural plaques is reported as the ratio between the number of screenees with
pleural plaques and specific number of screenees from each geographic area (adapted from https://commons.m.wikimedia.org)
Table 1 Demographics, biometrics, smoking history, and self-disclosure of asbestos exposure in the overall male population and
according to the presence of pleural plaques
All men
(n = 1570)
Men with pleural
plaques (n = 31)
Men without pleural
plaques (n = 1539)
pa
Age [years] 58 [54–62] 62 [57–66] 58 [54–62] 0.0054
Height [cm] 174 [170–178] 177 [170–180] 174 [170–178] 0.2536
Weight [kg] 80 [73–88] 83 [75–92] 80 [73–88] 0.101
BMI [kg/m^2] 26.4 [24.4–28.7] 27.2 [24.8–30.2] 26.4 [24.4–28.7] 0.1949
Smoking history
Current smoker 1007 (64.1%) 19 (61.3%) 988 (64.2%) 0.7103b
Former smoker 563 (35.9%) 12 (38.7%) 551(35.8%)
Duration [years] 39 [34–43] 40 [36–45] 39 [34–43] 0.2501
Pack years 40.0 [32.0–54.0] 41.0 [35.0–61.5] 40.0 [32.0–54.0] 0.6378
Self-disclosure of asbestos exposure 128 (8.2%) 8 (25.8%) 120 (7.8%) 0.0025b
aWilcoxon test
bFisher exact test
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until April 2016 (Table 3). In particular, the frequency
of lung cancer was 3/31 in men with pleural plaques
(1079/100,000 person-years) and 65/1539 in men
without pleural plaques (456/100,000 person-years),
with a non-statistically significant difference between
the groups (p = 0.148). In particular, all men with
pleural plaques showed stage 4 lung cancer. The mor-
tality from lung cancer in men with pleural plaques
was statistically higher compared to those without
pleural plaques (p = 0.015), whereas the mortality
from causes other than lung cancer was similar be-
tween the two groups.
A single mesothelioma was diagnosed in a subject who did
not have pleural plaques nor disclosed asbestos exposure.
Table 4 details the HR for overall or specific mortality
and for incidence of lung cancer in subjects with pleural
plaques. The HR for overall mortality was higher in men
with pleural plaques (HR 2.02), allegedly conditioned by
the exceptionally high HR for mortality from lung cancer
(HR 5.48). Of note, the HR for lung cancer incidence
was slightly but not significantly higher in men with
pleural plaques (HR 1.84).
Discussion
This study reports 2% prevalence of pleural plaques in
male participants of a lung cancer screening trial. Self-
disclosure of asbestos exposure was recorded in 8.2% of
male screenees, however a significant proportion of sub-
jects with pleural plaques were not aware of asbestos ex-
posure. Male screenees with pleural plaques showed a
trend for higher risk of lung cancer and significant in-
crease of lung cancer mortality compared to male
screenees without pleural plaques.
The relationship between asbestos exposure and lung
cancer has been investigated in several studies based on
occupational surveillance programs for asbestos workers
Table 2 LDCT features of pleural plaques detected by LDCT in
31/1570 men
LDCT features of pleural plaques N (%)
31 (100%)
Distribution by side:
Bilateral 28 (90%)
Unilateral 3 (10%)
Distribution by anatomical compartment:
More than one pleural compartment 21 (68%)
Subcostal only 9 (29%)
Para-mediastinal only 1 (3%)
Extent:
< 1 cm 1 (3%)
1 cm to 25% 25 (81%)
25 to 50% 4 (13%)
> 50% 1 (3%)
Thickness:
< 2 mm 1 (3%)
2–5 mm 7 (23%)
5–10 mm 19 (61%)
> 10 mm 4 (13%)
Calcification:
Calcified 21 (68%)
Non-calcified 10 (32%)
Aspect morphology:
Nodular aspect 19 (61%)
Smooth aspect 12 (39%)
Pleural effusion 1 (3%)
Table 3 Comparison of lung cancer frequency, stage, and cause of mortality according to presence pleural plaques. The table
includes events from the entire period of lung cancer screening (median follow-up 9.5 years). Notably, pleural plaques were searched
on baseline LDCT, therefore detection of pleural plaques either preceded (e.g. event at incidence rounds) or was synchronous
(e.g. event at baseline round) to each detailed event
All patients
(n = 1570)
Men with pleural
plaques (n = 31)
Men without pleural
plaques (n = 1539)
pa
Total person-years follow-up 14,533.3 278.0 14,255.3
Median person-years follow-up 9.5 9.4 9.5
Patients with lung cancer 68 (4.3%) 3 (9.7%) 65 (4.2%) 0.148
Lung cancer stage
I or II 39 (57.4%) 0 39 (60%) 0.073
III or IV 29 (42.6%) 3 (100%) 26 (40.0)
Total deaths 87 (5.5%) 4 (12.9%) 83 (5.4%) 0.088
Lung cancer deaths 27 (1.7%) 3 (9.7%) 24 (1.6%) 0.015
Deaths from causes other than lung cancer 60 (3.8%) 1 (3.2%) 59 (3.8%) 1.0
aFisher exact test
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[19–22]. Current or recent occupational exposure to as-
bestos is a known risk factor for lung cancer with a re-
ported two-fold increase of lung cancer risk among
smokers [7]. Mastrangelo et al. reported progressive de-
crease of relative risk of lung cancer after 15–20 years
since last exposure to asbestos [22], comparable to
smoking cessation. Nevertheless, increased risk of thor-
acic malignancy has been demonstrated also for ex-
tremely low exposure, such as non-occupational and
environmental exposure [23, 24]. Accordingly, several
lung cancer risk models for selection of lung cancer
screening population include asbestos exposure among
risk factors, even in case of non-occupational exposure
[3, 7]. Non-occupational exposure is likely to become
more relevant in industrialized countries were asbestos
ban was issued more than 20 years ago [10]. The assess-
ment of non-occupational exposure to asbestos is
extremely challenging, indeed more controversial that
the assessment of occupational exposure [25]. Self-
administered questionnaires have been employed to col-
lect data on asbestos exposure in participants of lung
cancer screening trials, despite this assessment demands
specialized operators for thorough investigation of po-
tential pollutant [26]. Our data showed that signs of as-
bestos exposure such pleural plaques were associated
with increased risk of lung cancer mortality, including
subjects who were not aware of occupational exposure.
The increased risk was independent from tobacco bur-
den. We encourage specific investigation of asbestos ex-
posure (both occupational and non-occupational) for
selection of subjects for lung cancer screening, even
when tobacco burden does not meet the reference level
for recruitment in such screening.
Previous lung cancer screening trials reported preva-
lence of asbestos-exposure ranging 5.6–7.3% [27, 28]. In
our study, similar results were obtained by self-disclosure
of asbestos exposure (overall self-disclosed exposure 6.5%
- data not reported in results), however almost 75% of
male screenees with pleural plaques did not disclose the
exposure. This observation confirms that self-disclosure of
asbestos exposure is not reliable, as it was reported in the
literature [29]. Ledda et al. reported a significant increase
of pleural plaques prevalence among subjects in an area
with high environmental concentration of fibrous amphi-
bole [30]. Of note, the CT features of pleural plaques re-
ported by Ledda in environmentally exposed subjects were
similar to those reported in our lung cancer screening
population, in particular the majority of subjects showed
plaque extent between 1 cm and 25% of pleural surface.
Pleural plaques in subjects that are not aware of exposure
to asbestos could be associated with non-occupational and
environmental exposure, and this should be particularly
emphasized in high-risk subjects that undergo lung cancer
screening by LDCT.
Bach et al. showed increase of lung cancer risk in associ-
ation to asbestos exposure in participants of lung cancer
screening trials [31]. In our study, screenees with pleural
plaques showed higher risk of lung cancer mortality com-
pared to the remainder screenees. We underline that
screenees with pleural plaques were diagnosed with ad-
vanced stage lung cancer. Hence, we suggest that in-
creased mortality could have been driven by a more
aggressive pattern of lung cancer in this group of screen-
ees. Again, it is apparent that assessment of pleural pla-
ques in lung cancer screening participant contributes to the
detection of subjects with minor or unknown exposure. For
this purpose, the objective assessment of pleural abnormal-
ities could be regarded as potential marker of increased risk
of lung cancer associated to asbestos exposure, and should
be investigated for post-test refinement of subjective risk of
lung cancer. Furthermore, from a demographic point of
view, detection of pleural plaques in screenees that are not
aware of the exposure should prompt active investigation
of environmental exposure to asbestos in specific areas.
Among occupationally exposed subjects, the correlation
between pleural plaques and lung cancer appears to be
lower compared to the relative risk associated with asbes-
tosis [10]. Both asbestosis and pleural plaques can be seen
on LDCT, however pleural plaques are more specific than
asbestosis findings in the absence of known exposure to
asbestos. Vehmas et al. reported significant increase of
lung cancer death in asbestos workers with pleural pla-
ques [4]. This report in workers exposed to asbestos is
confirmed by our data in the setting of lung cancer
screening trial. Screenees with pleural plaques showed a
trend for increased incidence of lung cancer, noteworthy
the clinical evolution of lung cancer in these subjects was
extremely aggressive. Lung cancer in subjects with pleural
plaques were all diagnosed in stage 4 and, thus, lung can-
cer mortality was significantly higher compared to screen-
ees with cancer diagnosis but without pleural plaques,
suggesting that mortality from lung cancer in subjects
with pleural plaques could be influenced by more factors
rather than the simple incidence of lung cancer (e.g. ag-
gressive biology). Risk models for post-test risk refinement
Table 4 Hazard ratios (HR)a of overall mortality, lung cancer
mortality and lung cancer occurrence among 1570 men
according to pleural findings
Pleural findings
HRa (95% CI)
Overall mortality (N = 87) 2.02 (0.73–5.56)
Mortality from lung cancer (N = 27) 5.48 (1.61–18.70)
Mortality from other causes than
lung cancer (N = 60)
0.70 (0.10–5.10)
Lung cancer incidence (N = 68) 1.84 (0.57–5.93)
aEstimated from Cox model adjusted for age, BMI, pack-years, self-disclosure
of asbestos exposure
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are mostly based on the presence and characteristics of
nodule and have been validated [32–34]. Looking forward
to screening implementation, post-test risk model enrich-
ment is fostered including other non-nodular LDCT find-
ings such as emphysema and other interstitial lung
abnormalities. Pleural plaques should be considered as
additional non-nodular finding for post-test risk model.
This study has some limitations. Asbestos exposure was
investigated by prospectively self-administered question-
naire, which is known to be inconsistent for assessment of
asbestos exposure. However, self-administered question-
naire is the affordable option for implementation in lung
cancer screening by LDCT. Moreover, asbestos exposure
was not further investigated in subjects with pleural pla-
ques and unaware of asbestos exposure. This could be
regarded as a limitation because the specific description of
exposure hazard in this subgroup could have provided in-
formation to improve anamnestic collection of this spe-
cific pollutant. Moreover, the asbestos exposure was
investigated with a binary question (e.g. yes or no), with-
out specific description of exposure duration and inten-
sity. This limitation was driven by the management and
financial plan within lung cancer screening trial with a
large population of screenees. We foster future studies
testing the correlation between detailed descriptors of as-
bestos exposure and lung cancer outcomes within lung
cancer screening programs. Finally, parenchymal signs of
asbestos exposure were not investigated, despite they are
associated with risk of lung cancer. Notably, parenchymal
signs were not scored because they are not specific for as-
bestos exposure when the exposure is not formally con-
firmed. It would be ideal that reliable information about
asbestos exposure in lung cancer screening allow specific
investigation of interstitial lung abnormalities related with
the exposure, since they are significantly related with the
risk of lung cancer [10].
Conclusions
In conclusion, pleural plaques can be detected in a
sizeable proportion of subjects undergoing lung cancer
screening by LDCT. Screenees with pleural plaques
show increased risk of lung cancer mortality, therefore
pleural plaques could be considered in risk models for
post-test refinement of subjective risk.
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